Serum matrix metalloproteinase (MMP) and tissue inhibitor of metalloproteinases-1 (TIMP-1) levels in patients with active RA not responding to anti-tumor necrosis factor (anti-TNF) therapy appear substantially decreased after RTX therapy [55]. This evidence concerns the gene TIMP1 and rheumatoid arthritis.